Hormone-biological therapy in breast cancer: Preclinical evidence, clinical studies and future directions

Current Cancer Drug Targets

Volumn 10, Issue 1, 2010, Pages 3-18

  Schiavon, G ^a   Tonini, G ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Breast cancer; Endocrine resistance; Hormone biological therapy; Signaling pathway; Targeted therapy

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; CAPECITABINE; DEFOROLIMUS; ERLOTINIB; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GEFITINIB; IMATINIB; LAPATINIB; LETROZOLE; LONAFARNIB; NAVELBINE; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VATALANIB; Z 222584;

ADJUVANT THERAPY; ASTHENIA; BRAIN METASTASIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER MODEL; CANCER RESEARCH; CANCER RESISTANCE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; MONOTHERAPY; NONHUMAN; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; SYSTEMATIC REVIEW; TUMOR PROMOTION; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL THERAPY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PATIENT SELECTION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 77950372289     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910790980278     Document Type: Review

References (103)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M. J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58, 71-96.
2. Polyak, K. Breast cancer: origins and evolution. J. Clin. Invest. 2007, 117, 3155-3163.
3. Perou, C. M.; Sorlie, T.; Eisen, M. B.; van de Rijn, M.; Jeffrey, S. S.; Rees, C. A.; Pollack, J. R.; Ross, D. T.; Johnsen, H.; Akslen, L. A.; Fluge, O.; Pergamenschikov, A.; Williams, C.; Zhu, S. X.; Lonning, P. E.; Borresen-Dale, A. L.; Brown, P. O.; Botstein, D. Molecular portraits of human breast tumours. Nature 2000, 406, 747-752.
4. Sorlie, T.; Perou, C. M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M. B.; van de Rijn, M.; Jeffrey, S. S.; Thorsen, T.; Quist, H.; Matese, J. C.; Brown, P. O.; Botstein, D.; Eystein Lonning, P.; Borresen-Dale, A. L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98, 10869-10874.
5. Peppercorn, J.; Perou, C. M.; Carey, L. A. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest. 2008, 26, 1-10.
6. Stingl, J.; Caldas, C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat. Rev. Cancer 2007, 7, 791-799.
7. Sorlie, T.; Tibshirani, R.; Parker, J.; Hastie, T.; Marron, J. S.; Nobel, A.; Deng, S.; Johnsen, H.; Pesich, R.; Geisler, S.; Demeter, J.; Perou, C. M.; Lonning, P. E.; Brown, P. O.; Borresen-Dale, A. L.; Botstein, D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 2003, 100, 8418-8423.
8. Sotiriou, C.; Neo, S. Y.; McShane, L. M.; Korn, E. L.; Long, P. M.; Jazaeri, A.; Martiat, P.; Fox, S. B.; Harris, A. L.; Liu, E. T. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. USA 2003, 100, 10393-10398.
9. Olopade, O. I.; Grushko, T. A.; Nanda, R.; Huo, D. Advances in breast cancer: pathways to personalized medicine. Clin. Cancer Res. 2008, 14, 7988-7999.
10. Fan, C.; Oh, D. S.; Wessels, L.; Weigelt, B.; Nuyten, D. S.; Nobel, A. B.; van't Veer, L. J.; Perou, C. M. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 2006, 355, 560-569.
11. Hu, Z.; Fan, C.; Oh, D. S.; Marron, J. S.; He, X.; Qaqish, B. F.; Livasy, C.; Carey, L. A.; Reynolds, E.; Dressler, L.; Nobel, A.; Parker, J.; Ewend, M. G.; Sawyer, L. R.; Wu, J.; Liu, Y.; Nanda, R.; Tretiakova, M.; Ruiz Orrico, A.; Dreher, D.; Palazzo, J. P.; Perreard, L.; Nelson, E.; Mone, M.; Hansen, H.; Mullins, M.; Quackenbush, J. F.; Ellis, M. J.; Olopade, O. I.; Bernard, P. S.; Perou, C. M. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7, 96.
12. van 't Veer, L. J.; Dai, H.; van de Vijver, M. J.; He, Y. D.; Hart, A. A.; Mao, M.; Peterse, H. L.; van der Kooy, K.; Marton, M. J.; Witteveen, A. T.; Schreiber, G. J.; Kerkhoven, R. M.; Roberts, C.; Linsley, P. S.; Bernards, R.; Friend, S. H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415, 530-536.
13. Paik, S.; Shak, S.; Tang, G.; Kim, C.; Baker, J.; Cronin, M.; Baehner, F. L.; Walker, M. G.; Watson, D.; Park, T.; Hiller, W.; Fisher, E. R.; Wickerham, D. L.; Bryant, J.; Wolmark, N. A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N. Engl. J. Med. 2004, 351, 2817-2826.
14. Chang, H. Y.; Nuyten, D. S.; Sneddon, J. B.; Hastie, T.; Tibshirani, R.; Sorlie, T.; Dai, H.; He, Y. D.; van't Veer, L. J.; Bartelink, H.; van de Rijn, M.; Brown, P. O.; van de Vijver, M. J. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl. Acad. Sci. USA 2005, 102, 3738-3743.
15. Kato, S.; Endoh, H.; Masuhiro, Y.; Kitamoto, T.; Uchiyama, S.; Sasaki, H.; Masushige, S.; Gotoh, Y.; Nishida, E.; Kawashima, H.; Metzger, D.; Chambon, P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995, 270, 1491-1494.
16. Johnston, S. R.; Head, J.; Pancholi, S.; Detre, S.; Martin, L. A.; Smith, I. E.; Dowsett, M. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin. Cancer Res. 2003, 9, 524S-532S.
17. Shou, J.; Massarweh, S.; Osborne, C. K.; Wakeling, A. E.; Ali, S.; Weiss, H.; Schiff, R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst. 2004, 96, 926-935.
18. Johnston, S. R.; Dowsett, M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat. Rev. Cancer 2003, 3, 821-831.
19. Pietras, R. J; Szego, C. M. Plasma membrane for steroid hormones in cell signalling and nuclear function. In Endocrinology: Basic and Clinical Principles; 2nd ed.; Melmed, S.; Conn, P. M.; Eds.; Humana Press: Totowa, NJ, 2005, pp. 67-84.
20. Winer, E. P. Optimizing endocrine therapy for breast cancer. J. Clin. Oncol. 2005, 23, 1609-1610.
21. Carlson, R. W. (Panel chair). NCCN Practice Guidelines in Oncology. Breast Cancer v.2.2008. http://www.nccn.org/professionals/physician-gls/PDF/ breast.pdf
22. Osborne, C. K.; Coronado-Heinsohn, E. B.; Hilsenbeck, S. G.; McCue, B. L.; Wakeling, A. E.; McClelland, R. A.; Manning, D. L.; Nicholson, R. I. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J. Natl. Cancer Inst. 1995, 87, 746-750.
23. Osborne, C. K.; Bardou, V.; Hopp, T. A.; Chamness, G. C.; Hilsenbeck, S. G.; Fuqua, S. A.; Wong, J.; Allred, D. C.; Clark, G. M.; Schiff, R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl. Cancer Inst. 2003, 95, 353-361.
24. Font de Mora, J.; Brown, M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol. Cell Biol. 2000, 20, 5041-5047.
25. Ellis, M. J.; Coop, A.; Singh, B.; Mauriac, L.; Llombert-Cussac, A.; Janicke, F.; Miller, W. R.; Evans, D. B.; Dugan, M.; Brady, C.; Quebe-Fehling, E.; Borgs, M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. 2001, 19, 3808-3816.
26. Dowsett, M.; Cuzick, J.; Wale, C.; Howell, T.; Houghton, J.; Baum, M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J. Clin. Oncol. 2005, 23, 7512-7517.
27. Martin, L. A.; Farmer, I.; Johnston, S. R.; Ali, S.; Marshall, C.; Dowsett, M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J. Biol. Chem. 2003, 278, 30458-30468.
28. Santen, R. J.; Song, R. X.; Zhang, Z.; Kumar, R.; Jeng, M. H.; Masamura, A.; Lawrence, J., Jr.; Berstein, L.; Yue, W. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr. Relat. Cancer 2005, 12(Suppl 1), S61-73.
29. Liu, Y.; el-Ashry, D.; Chen, D.; Ding, I. Y.; Kern, F. G. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res. Treat. 1995, 34, 97-117.
30. Pietras, R. J.; Arboleda, J.; Reese, D. M.; Wongvipat, N.; Pegram, M. D.; Ramos, L.; Gorman, C. M.; Parker, M. G.; Sliwkowski, M. X.; Slamon, D. J. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995, 10, 2435-2446.
31. Bunone, G.; Briand, P. A.; Miksicek, R. J.; Picard, D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996, 15, 2174-2183.
32. Long, B. J.; Jelovac, D.; Handratta, V.; Thiantanawat, A.; MacPherson, N.; Ragaz, J.; Goloubeva, O. G.; Brodie, A. M. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J. Natl. Cancer Inst. 2004, 96, 456-465.
33. Sabnis, G. J.; Macedo, L. F.; Goloubeva, O.; Schayowitz, A.; Brodie, A. M. Stopping treatment can reverse acquired resistance to letrozole. Cancer Res. 2008, 68, 4518-4524.
34. Sabnis, G.; Schayowitz, A.; Goloubeva, O.; Macedo, L.; Brodie, A. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res. 2009, 69, 1416-1428.
35. Gligorov, J.; Azria, D.; Namer, M.; Khayat, D.; Spano, J. P. Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives. Crit. Rev. Oncol. Hematol. 2007, 64, 115-128.
36. Dowsett, M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr. Relat. Cancer 2001, 8, 191-195.
37. Ring, A.; Dowsett, M. Human epidermal growth factor receptor-2 and hormonal therapies: clinical implications. Clin. Breast Cancer 2003, 4(Suppl 1), S34-41.
38. Wright, C.; Angus, B.; Nicholson, S.; Sainsbury, J. R.; Cairns, J.; Gullick, W. J.; Kelly, P.; Harris, A. L.; Horne, C. H. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989, 49, 2087-2090.
39. Arpino, G.; Weiss, H.; Lee, A. V.; Schiff, R.; De Placido, S.; Osborne, C. K.; Elledge, R. M. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J. Natl. Cancer Inst. 2005, 97, 1254-1261.
40. Leary, A. F.; Sirohi, B.; Johnston, S. R. Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer. Breast Cancer Res. 2007, 9, 112.
41. Vogel, C. L.; Cobleigh, M. A.; Tripathy, D.; Gutheil, J. C.; Harris, L. N.; Fehrenbacher, L.; Slamon, D. J.; Murphy, M.; Novotny, W. F.; Burchmore, M.; Shak, S.; Stewart, S. J.; Press, M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20, 719-726.
42. Marcom, P. K.; Isaacs, C.; Harris, L.; Wong, Z. W.; Kommarreddy, A.; Novielli, N.; Mann, G.; Tao, Y.; Ellis, M. J. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res. Treat. 2007, 102, 43-49.
43. Kaufman, B.; Mac , J. R.; Clemens, M. R.; Bapsy, P. P.; Vaid, A.; Wardley, A.; Tjulandin, S.; Jahn, M.; Lehle, M.; Feyereislova, A.; Revil, C.; Jones, A. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J. Clin. Oncol. 2009, 27, 5529-5537.
44. Burstein, H. J.; Storniolo, A. M.; Franco, S.; Forster, J.; Stein, S.; Rubin, S.; Salazar, V. M.; Blackwell, K. L. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann. Oncol. 2008, 19, 1068-1074.
45. Chu, Q. S.; Cianfrocca, M. E.; Goldstein, L. J.; Gale, M.; Murray, N.; Loftiss, J.; Arya, N.; Koch, K. M.; Pandite, L.; Fleming, R. A.; Paul, E.; Rowinsky, E. K. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin. Cancer Res. 2008, 14, 4484-4490.
46. Johnston, S.; Pippen, J., Jr.; Pivot, X.; Lichinitser, M.; Sadeghi, S.; Dieras, V.; Gomez, H. L.; Romieu, G.; Manikhas, A.; Kennedy, M. J.; Press, M. F.; Maltzman, J.; Florance, A.; O'Rourke, L.; Oliva, C.; Stein, S.; Pegram, M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 2009, 27, 5538-5546.
47. Klijn, J. G.; Berns, P. M.; Schmitz, P. I.; Foekens, J. A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr. Rev. 1992, 13, 3-17.
48. Bevilacqua, P.; Gasparini, G.; Dal Fior, S.; Corradi, G. Immunocytochemical determination of epidermal growth factor receptor with monoclonal EGFR1 antibody in primary breast cancer patients. Oncology 1990, 47, 313-317.
49. Falette, N.; Lefebvre, M. F.; Meggouh, F.; Eynard, M.; Garin, E.; Saez, S. Measurement of occupied and non-occupied epidermal growth factor receptor sites in 216 human breast cancer biopsies. Breast Cancer Res. Treat. 1992, 20, 177-183.
50. Wrba, F.; Reiner, A.; Ritzinger, E.; Holzner, J. H.; Reiner, G. Expression of epidermal growth factor receptors (EGFR) on breast carcinomas in relation to growth fractions, estrogen receptor status and morphological criteria. An immunohistochemical study. Pathol. Res. Pract. 1988, 183, 25-29.
51. Vickers, P. J.; Dickson, R. B.; Shoemaker, R.; Cowan, K. H. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol. Endocrinol. 1988, 2, 886-892.
52. Long, B.; McKibben, B. M.; Lynch, M.; van den Berg, H. W. Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line. Br. J. Cancer 1992, 65, 865-869.
53. van den Berg, H. W.; Claffie, D.; Boylan, M.; McKillen, J.; Lynch, M.; McKibben, B. Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth factor I receptor expression. Br. J. Cancer 1996, 73, 477-481.
54. Ranson, M. ZD1839 (Iressa): for more than just non-small cell lung cancer. Oncologist 2002, 7(Suppl 4), 16-24.
55. Wakeling, A. E.; Barker, A. J.; Davies, D. H.; Brown, D. S.; Green, L. R.; Cartlidge, S. A.; Woodburn, J. R. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res. Treat. 1996, 38, 67-73.
56. Wakeling, A. E.; Guy, S. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Barker, A. J.; Gibson, K. H. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002, 62(20), 5749-5754.
57. Ciardiello, F.; Caputo, R.; Bianco, R.; Damiano, V.; Pomatico, G.; De Placido, S.; Bianco, A. R.; Tortora, G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 2000, 6, 2053-2063.
58. Gee, J. M.; Harper, M. E.; Hutcheson, I. R.; Madden, T. A.; Barrow, D.; Knowlden, J. M.; McClelland, R. A.; Jordan, N.; Wakeling, A. E.; Nicholson, R. I. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003, 144, 5105-5117.
59. Anido, J.; Matar, P.; Albanell, J.; Guzman, M.; Rojo, F.; Arribas, J.; Averbuch, S.; Baselga, J. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin. Cancer Res. 2003, 9, 1274-1283.
60. Gutteridge, E.; Agrawal, A.; Nicholson, R.; Leung Cheung, K.; Robertson, J.; Gee, J. The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: A phase II study. Int. J. Cancer 2009, [Epub ahead of print].
61. Smith, I. E.; Walsh, G.; Skene, A.; Llombart, A.; Mayordomo, J. I.; Detre, S.; Salter, J.; Clark, E.; Magill, P.; Dowsett, M. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J. Clin. Oncol. 2007, 25, 3816-3822.
62. Polychronis, A.; Sinnett, H. D.; Hadjiminas, D.; Singhal, H.; Mansi, J. L.; Shivapatham, D.; Shousha, S.; Jiang, J.; Peston, D.; Barrett, N.; Vigushin, D.; Morrison, K.; Beresford, E.; Ali, S.; Slade, M. J.; Coombes, R. C. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor- positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol. 2005, 6, 383-391.
63. Dickler, M. N.; Cobleigh, M. A.; Miller, K. D.; Klein, P. M.; Winer, E. P. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res. Treat. 2009, 115, 115-121.
64. Guix, M.; Granja Nde, M.; Meszoely, I.; Adkins, T. B.; Wieman, B. M.; Frierson, K. E.; Sanchez, V.; Sanders, M. E.; Grau, A. M.; Mayer, I. A.; Pestano, G.; Shyr, Y.; Muthuswamy, S.; Calvo, B.; Krontiras, H.; Krop, I. E.; Kelley, M. C.; Arteaga, C. L. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J. Clin. Oncol. 2008, 26, 897-906.
65. Clark, G. J.; Der, C. J. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res. Treat. 1995, 35, 133-144.
66. Norgaard, P.; Law, B.; Joseph, H.; Page, D. L.; Shyr, Y.; Mays, D.; Pietenpol, J. A.; Kohl, N. E.; Oliff, A.; Coffey, R. J., Jr.; Poulsen, H. S.; Moses, H. L. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin. Cancer Res. 1999, 5, 35-42.
67. Clark, G. J.; Kinch, M. S.; Gilmer, T. M.; Burridge, K.; Der, C. J. Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers. Oncogene 1996, 12, 169-176.
68. Head, J.; Johnston, S. R. New targets for therapy in breast cancer: farnesyltransferase inhibitors. Breast Cancer Res. 2004, 6, 262-268.
69. Prendergast, G. C.; Davide, J. P.; deSolms, S. J.; Giuliani, E. A.; Graham, S. L.; Gibbs, J. B.; Oliff, A.; Kohl, N. E. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol. Cell Biol. 1994, 14, 4193-4202.
70. Miquel, K.; Pradines, A.; Sun, J.; Qian, Y.; Hamilton, A. D.; Sebti, S. M.; Favre, G. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res. 1997, 57, 1846-1850.
71. Sepp-Lorenzino, L.; Rosen, N. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. J. Biol. Chem. 1998, 273, 20243-20251.
72. Kelland, L. R.; Smith, V.; Valenti, M.; Patterson, L.; Clarke, P. A.; Detre, S.; End, D.; Howes, A. J.; Dowsett, M.; Workman, P.; Johnston, S. R. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin. Cancer Res. 2001, 7, 3544-3550.
73. Martin, L. A.; Head, J. E.; Pancholi, S.; Salter, J.; Quinn, E.; Detre, S.; Kaye, S.; Howes, A.; Dowsett, M.; Johnston, S. R. The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. Mol. Cancer Ther. 2007, 6, 2458-2467.
74. Ellis, C. A.; Vos, M. D.; Wickline, M.; Riley, C.; Vallecorsa, T.; Telford, W. G.; Zujewskil, J.; Clark, G. J. Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines. Breast Cancer Res. Treat. 2003, 78, 59-67.
75. Basso, A. D.; Mirza, A.; Liu, G.; Long, B. J.; Bishop, W. R.; Kirschmeier, P. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J. Biol. Chem. 2005, 280, 31101-31108.
76. Lebowitz, P. F.; Eng-Wong, J.; Widemann, B. C.; Balis, F. M.; Jayaprakash, N.; Chow, C.; Clark, G.; Gantz, S. B.; Venzon, D.; Zujewski, J. A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer. Clin. Cancer Res. 2005, 11, 1247-1252.
77. Johnston, S. R.; Semiglazov, V. F.; Manikhas, G. M.; Spaeth, D.; Romieu, G.; Dodwell, D. J.; Wardley, A. M.; Neven, P.; Bessems, A.; Park, Y. C.; De Porre, P. M.; Perez Ruixo, J. J.; Howes, A. J. A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res. Treat. 2008, 110, 327-335.
78. Li, T.; Christos, P. J.; Sparano, J. A.; Hershman, D. L.; Hoschander, S.; O'Brien, K.; Wright, J. J.; Vahdat, L. T. Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205. Ann. Oncol. 2009, 20, 642-647.
79. Yu, K.; Toral-Barza, L.; Discafani, C.; Zhang, W. G.; Skotnicki, J.; Frost, P.; Gibbons, J. J. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer 2001, 8, 249-258.
80. Boulay, A.; Rudloff, J.; Ye, J.; Zumstein-Mecker, S.; O'Reilly, T.; Evans, D. B.; Chen, S.; Lane, H. A. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin. Cancer Res. 2005, 11, 5319-5328.
81. deGraffenried, L. A.; Friedrichs, W. E.; Russell, D. H.; Donzis, E. J.; Middleton, A. K.; Silva, J. M.; Roth, R. A.; Hidalgo, M. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin. Cancer Res. 2004, 10, 8059-8067.
82. Clark, A. S.; West, K.; Streicher, S.; Dennis, P. A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 2002, 1, 707-717.
83. Pancholi, S.; Lykkesfeldt, A. E.; Hilmi, C.; Banerjee, S.; Leary, A.; Drury, S.; Johnston, S.; Dowsett, M.; Martin, L. A. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr. Relat. Cancer 2008, 15, 985-1002.
84. Johnston, S. R. Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists. Int. J. Gynecol. Cancer 2006, 16(Suppl 2), 543-548.
85. O'Reilly, K. E.; Rojo, F.; She, Q. B.; Solit, D.; Mills, G. B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D. J.; Ludwig, D. L.; Baselga, J.; Rosen, N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66, 1500-1508.
86. Sarbassov, D. D.; Guertin, D. A.; Ali, S. M.; Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307, 1098-1101.
87. Johnston, S. R. Integration of endocrine therapy with targeted agents. Breast Cancer Res. 2008, 10(Suppl 4), S20.
88. Baselga, J.; Semiglazov, V.; van Dam, P.; Manikhas, A.; Bellet, M.; Mayordomo, J.; Campone, M.; Kubista, E.; Greil, R.; Bianchi, G.; Steinseifer, J.; Molloy, B.; Tokaji, E.; Gardner, H.; Phillips, P.; Stumm, M.; Lane, H. A.; Dixon, J. M.; Jonat, W.; Rugo, H. S. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 2009, 27, 2630-2637.
89. Awada, A.; Cardoso, F.; Fontaine, C.; Dirix, L.; De Greve, J.; Sotiriou, C.; Steinseifer, J.; Wouters, C.; Tanaka, C.; Zoellner, U.; Tang, P.; Piccart, M. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur. J. Cancer 2008, 44, 84-91.
90. Saaristo, A.; Karpanen, T.; Alitalo, K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 2000, 19, 6122-6129.
91. Gasparini, G. In: Angiogenesis in breast cancer: role in biology; tumor progression and prognosis. Breast cancer: molecular genetics; pathogenesis; and therapeutics. Bowcock, A. M.; Ed.; Humana Press: Totowa, NJ, 1999, pp. 347-371.
92. Kerbel, R. S. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000, 21, 505-515.
93. Bange, J.; Zwick, E.; Ullrich, A. Molecular targets for breast cancer therapy and prevention. Nat. Med. 2001, 7, 548-552.
94. Traina, T. A.; Rugo, H. S.; Dickler, M. Bevacizumab for advanced breast cancer. Hematol. Oncol. Clin. North Am. 2007, 21, 303-319.
95. Banerjee, S.; Pancholi, S.; A'Hern, R.; Ghazoui, Z.; Smith, I. E.; Dowsett, M.; Martin, L. A. The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer. Clin. Cancer Res. 2008, 14, 2656-2663.
96. Kim, L. S.; Huang, S.; Lu, W.; Lev, D. C.; Price, J. E. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin. Exp. Metastasis 2004, 21, 107-118.
97. Sweeney, C. J.; Miller, K. D.; Sissons, S. E.; Nozaki, S.; Heilman, D. K.; Shen, J.; Sledge, G. W., Jr. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001, 61, 3369-3372.
98. Torrisi, R.; Bagnardi, V.; Cardillo, A.; Bertolini, F.; Scarano, E.; Orlando, L.; Mancuso, P.; Luini, A.; Calleri, A.; Viale, G.; Goldhirsch, A.; Colleoni, M. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. Br. J. Cancer 2008, 99, 1564-1571.
99. Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64, 7099-7109.
100. Wilhelm, S.; Chien, D. S. BAY 43-9006: preclinical data. Curr. Pharm. Des. 2002, 8, 2255-2257.
101. Wilhelm, S. M.; Adnane, L.; Newell, P.; Villanueva, A.; Llovet, J. M.; Lynch, M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 2008, 7, 3129-3140.
102. Carvalho, I.; Milanezi, F.; Martins, A.; Reis, R. M.; Schmitt, F. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res. 2005, 7, R788-795.
103. Hiraga, T.; Nakamura, H. Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals. Int. J. Cancer 2009, 124, 215-222.